PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS

• J. N. Allan,
• A. P. Skarbnik,
• N. Emechebe,
• H. Alhasani,
• B. S. Manzoor

Affiliations

J. N. Allan

1 Weill Cornell Medicine University Medical Center, New York

A. P. Skarbnik

2 Novant Health, Charlotte

N. Emechebe

3 AbbVie, North Chicago, United States of America

H. Alhasani

3 AbbVie, North Chicago, United States of America

B. S. Manzoor

3 AbbVie, North Chicago, United States of America